• iKarios
  • NPHL

A short history:

iKaryos Diagnostics was developed to deliver better cancer diagnostics to physicians and patients. The company was originally privately financed and is now operated by the Department of Pathology and Microbiology at the University of Nebraska Medical Center.

Medical Director:

Julia A. Bridge, M.D.

Julia A. Bridge, M.D., FACMG, is a Professor in the UNMC Departments of Pathology, Pediatrics and Orthopaedic Surgery. She is Director of UNMC's Molecular Diagnostic Laboratory for Sarcoma Gene Rearrangements, Director of the UNMC Tissue Bank and Associate Director of the Clinical Cytogenetic Laboratory. Dr. Bridge serves on the editorial boards of Cancer Genetics, Cancer Cytopathology, Modern Pathology, and Journal of Orthopaedic Science as well as several national committees including the Soft Tissue Sarcoma and Ewing’s sarcoma committees for the Children’s Oncology Group (COG), the Molecular Oncology Committee for the College of American Pathologists (CAP) and the VA Genomic Medicine Program Advisory Committee (GMPAC). After earning her M.D. degree from the University of Nebraska College of Medicine, she completed a pathology residency at the University of Kansas Medical Center, a fellowship in clinical cytogenetics at the University of Nebraska Medical Center and a fellowship in molecular biology at the Southwest Biomedical Research Institute in Arizona. Board certified by the American Board of Pathology and the American Board of Medical Genetics, Dr. Bridge's research interests include the genetics of bone and soft tissue tumors.

Founding Scientists

Robert Klein, Ph.D.

Dr. Klein has nearly 20 years biotechnology experience at multiple companies including Rinat Neuroscience, Genentech, and Deltagen. Dr. Klein has held senior positions including vice president and CSO in both the scientific and business areas with a focus in new technology development, pre–clinical research, and mergers & acquisitions. Dr. Klein received his bachelor's degree in Biochemistry from UC Berkeley and his Ph.D. in Biology from MIT.

Jill Hagenkord, M.D.

Dr. Hagenkord is a board-certified molecular pathologist and she obtained her MD from Stanford University School of Medicine in 1999. After residency training in pathology at UCSF and University of Iowa, Dr. Hagenkord completed fellowships in Pathology/Oncology Informatics and Molecular Genetic Pathology at the University of Pittsburgh. Dr. Hagenkord has been performing virtual karyotyping of human tumors, hematologic and solid, since 2006.

Shera Kash, Ph.D.

Dr. Kash obtained her PhD from Baylor College of Medicine in Molecular Genetics and did post-doctoral training at UCSF. Prior to coming to iKaryos, Dr. Kash was Vice President of Operations at Deltagen, Inc, a Silicon Valley biotechnology company. Dr. Kash has 10 years of management experience in biotechnology, experience establishing CLIA-certified clinical laboratories, and dozens of scientific publications in peer reviewed journals.